Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Change in Receivables (2023 - 2025)

Metagenomi (MGX) has disclosed Change in Receivables for 3 consecutive years, with -$655000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 198.05% to -$655000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$952000.0, a 20.27% increase, with the full-year FY2025 number at -$952000.0, up 20.27% from a year prior.
  • Change in Receivables was -$655000.0 for Q4 2025 at Metagenomi, down from $87000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.6 million in Q3 2023 to a low of -$1.5 million in Q4 2023.
  • A 3-year average of -$202300.0 and a median of -$307000.0 in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 145.35% in 2024, then plummeted 198.05% in 2025.
  • Metagenomi's Change in Receivables stood at -$1.5 million in 2023, then surged by 145.35% to $668000.0 in 2024, then tumbled by 198.05% to -$655000.0 in 2025.
  • Per Business Quant, the three most recent readings for MGX's Change in Receivables are -$655000.0 (Q4 2025), $87000.0 (Q3 2025), and -$139000.0 (Q2 2025).